Biocartis Closes $41.3M Series B to Further Develop Molecular Dx Platform
April 08, 2010
Biocartis Closes $41.3M Series B to Further Develop Molecular Dx Platform
The Swiss firm said that it will use the cash to accelerate development and validation of the first version of its forthcoming molecular diagnostics platform, which will incorporate nucleic acid sample prep technology recently acquired from Royal Philips Electronics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BioMérieux Buys Argene to Bolster Test Menu for Biocartis MDx Platform
July 21, 2011 / PCR Insider - Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials
May 19, 2011 / PCR Insider - Biocartis Buys Philips Molecular Dx Platform 'Inspired' by Consumer Electronics Tech
February 11, 2010 / PCR Insider - Akonni Biosystems Wins NIH Grant to Develop Low-Cost NA Isolation Device
October 2, 2012 / GenomeWeb Daily News - Immunexpress, Biocartis, Debiopharm to Further Develop Sepsis MDx
June 19, 2012 / GenomeWeb Daily News